Expired activity

Please go to the PowerPak homepage and select a course.

BCMA-Targeted Therapies in Multiple Myeloma: What the Pharmacist Needs to Know

This continuing pharmacy education activity is provided by

This educational activity is supported by an educational grant from GlaxoSmithKline.

Activity Description

Although the median overall survival rate for patients with multiple myeloma (MM) has nearly doubled during the last 2 decades, MM remains incurable and a majority of patients develop relapsed disease. The prognosis is poor among these patients, with a median overall survival of just over 1 year after 3 lines of therapy. Although improvements in diagnosis, risk stratification, and treatment continue—with multiple agents now available from various drug classes—additional novel agents with improved efficacy and safety are still needed, particularly in the relapsed or refractory setting. Several therapies have recently been approved that target B-cell maturation antigen (BCMA), a transmembrane protein expressed by malignant plasma cells that is involved in plasma and B-cell survival, B-cell maturation and growth, and activation of regulatory T cells. In this activity, expert clinicians will review the current treatment guidelines and the most recent clinical data supporting the use of BCMA-targeted for relapsed/refractory MM, define the disease and clinical characteristics of patients for whom BCMA-targeted therapy is appropriate, and describe the optimal multidisciplinary care coordination strategies for the management of treatment-emergent adverse events in patients receiving BCMA-targeted therapies.

Target Audience

The intended audience for this activity is managed care pharmacists, oncology pharmacists, and other health care professionals involved in the management of patients with multiple myeloma.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Outline current guideline recommendations for the treatment of relapsed/refractory multiple myeloma.
• Review the patient, disease, and treatment characteristics that may make patients likely to benefit from BCMA-targeted therapies.
• Assess the latest clinical efficacy data and safety profiles for recently approved BCMA-targeted therapies for patients with relapsed/refractory multiple myeloma.
• Define multidisciplinary care coordination strategies for the recognition and management of adverse events in patients receiving BCMA-targeted therapies.

Activity Chair

Ryan Haumschild, PharmD, MS, MBA
Director of Pharmacy
Emory Healthcare
Winship Cancer Institute
Atlanta, GA

Faculty

Craig Freyer, PharmD, BCOP
Clinical Pharmacy Specialist
Hematology/Oncology, Stem Cell Transplant, and Cellular Therapy
Penn Medicine
Hospital of the University of Pennsylvania – Pavilion
Philadelphia, PA

Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital
Harvard Medical School
Boston, MA

Saad Usmani, MD, MBA, FACP
Chief of Myeloma Service
Member, Memorial Sloan Kettering Cancer Center
Attending Physician, Myeloma, Cellular Therapy and Adult BMT
New York, NY

Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Jennifer Frederick, PharmD, BCPS

Accreditation Statements

Designation Statements

This program is acceptable for 1.25 contact hour of Accreditation Council for Pharmacy Education (ACPE) Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-22-035-H01-P, effective 12/22/2022. This is a knowledge-based activity and there is no fee to attend.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor within 30 days.

This enduring material is approved for 1 year from the date of original release, December 22, 2022, to December 21, 2023.

How to Participate in this Activity and Obtain CE Credit

To participate in this CE activity, you must read the learning objectives, answer the pretest questions, view the content, and complete the CE posttest and evaluation within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded.  If you successfully complete the posttest (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.

Disclosures

Vindico Medical Education adheres to the Accreditation Council for Pharmacy Education (ACPE’s) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Activity Chair and Faculty report the following relationship(s)

Craig Freyer, PharmD, BCOP
Advisor: Servier

Ryan Haumschild, PharmD, MS, MBA
Consultant: GlaxoSmithKline

Noopur Raje, MD
Advisor: Caribou Biosciences, Immuneel
Consultant: AbbVie, Amgen, Bristol Myers Squibb, Janssen, Pfizer, Sanofi, Takeda

Saad Usmani, MD, MBA, FACP
Consultant: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Genentech, Gilead, GlaxoSmithKline, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SkylineDX, Takeda, TeneoBio
Speaker Contracted by Ineligible Company: Amgen, Bristol Myers Squibb, Janssen, Sanofi
Independent Research Contractor: Amgen, Array Biopharma, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda

Planners/Reviewers reports the following relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Jennifer Frederick, PharmD, BCPS
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CE Questions?

Contact us at cme@vindicoCME.com